Chiron, J&J, Zarix deal

CHIR granted Zarix exclusive worldwide rights to develop and market rM-CSF recombinant human macrophage colony stimulating factor in the fields of infectious diseases and cancer. CHIR will receive an upfront license fee plus milestones and royalties. Zarix expects to begin Phase III testing of the compound in combination with antifungal therapy to increase the response rate of patients with fungal infections. ...